Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Launched by MAHIDOL UNIVERSITY · Jul 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called olanzapine to help patients with cancer who are experiencing anorexia-cachexia syndrome. This syndrome is characterized by a loss of appetite and significant weight loss, which can occur even in patients who are not receiving chemotherapy. The goal of the trial is to determine if olanzapine can effectively reduce these symptoms and improve the quality of life for patients with advanced cancer.

To be eligible for the trial, participants must have a diagnosis of advanced cancer and have experienced a loss of appetite along with at least a 5% weight loss in the last six months. They should be able to take pills and complete questionnaires about their health. However, individuals who are currently undergoing chemotherapy, have certain health conditions, or are pregnant cannot participate. If you decide to join the trial, you will receive the medication and be monitored by healthcare professionals who will help assess its effects on your appetite and overall well-being. This study is currently looking for participants, and everyone, regardless of gender, aged 65 to 74 or older, is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • pathologically or cytologically metastatic or locally advanced cancer
• • anorexia and \>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \>=5
• • ECOG performance status 0-3
• • able to complete questionaire and able to swallow pills
• Exclusion Criteria:
• • receiving chemotherapy or anti-cancer systemic therapy
• • life expectancy longer than 1 month
• • received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
• • surgery within 4 weeks
• • pregnancy
• • serum bilirubin \> 2 mg/dl or serum Cr \> 2 mg/dl
• • current use of olanzapine or other antipsychotic drug
• • known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months